Maggie M. Abbassi

Maggie M. Abbassi

Auto-generated profile, based on publicly available information

Maggie M. Abbassi

Department of Clinical Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2025 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
MMMona S. Abdel Monem
Mona S. Abdel Monem
AAAbdulmoneim Adel
Abdulmoneim Adel
MAMaggie M. Abbassi
Maggie M. Abbassi
DADoaa H. Abdelaziz
Doaa H. Abdelaziz
MHMohamed Hassany
Mohamed Hassany
NSNirmeen A. Sabry
Nirmeen A. Sabry

22 February 2021 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
MMMona S. Abdel Monem
Mona S. Abdel Monem
SFSamar F. Farid
Samar F. Farid
MAMaggie M. Abbassi
Maggie M. Abbassi
IYILHAM YOUSSRY
ILHAM YOUSSRY
NANevine G. Andraues
Nevine G. Andraues
MEManal H. El‐Sayed
Manal H. El‐Sayed

8 August 2023 in European Journal of Nutrition
Verified
Journal Article
Open access
PDF file
AAAmani M. Ali
Amani M. Ali
MAMaggie M. Abbassi
Maggie M. Abbassi
NSNirmeen A. Sabry
Nirmeen A. Sabry
MFMay Fawzi
May Fawzi
SMShrook Mousa
Shrook Mousa
Purpose: The purpose of this study was to assess the possible clinical effects of vitamin K4 supplementation in individuals with type 2 diabetes namely insulin resistance, glycaemic control, and lipid profile. Methods: This was a prospective randomised double-blind placebo-controlled clinical trial. A total of 106 patients were randomised to receive either 1 mg of vitamin K4 (menadiol diacetate) or placebo for 24 weeks. Results: Ninety patients (n = 45 in each study group) were included in the final analysis. After 24 weeks, homeostatic model assessment of insulin resistance (HOMA-IR) (16.54 ± 7.81 vs. 29.09 ± 36.56, P = 0.027) and fasting serum insulin (FSI) (6.86 ± 3.45 vs. 11.13 ± 12.66 µU/ml, P = 0.032) were significantly lower in the vitamin K group compared to placebo. Additionally, triglycerides (TG) (144.94 ± 50.7 vs. 172.8 ± 101.5 mg/dl, P = 0.031) and very low-density lipoproteins (VLDL) levels (28.9 ± 9.88 vs. 34.6 ± 20.30 mg/dl, P = 0.027) decreased significantly in the vitamin K group after 24 weeks compared to baseline. Moreover, more patients in the vitamin K group (35.6%) had their antidiabetic medication doses reduced after 24 weeks compared to placebo (13.3%, P = 0.029). Conclusion: Vitamin K4 supplementation for 24 weeks is capable of improving insulin resistance and TG levels in individuals with type 2 diabetes. In addition, the improvement in insulin resistance was reflected in the decrease in antidiabetic medication doses. However, it did not affect fasting plasma glucose (FPG) or glycated haemoglobin (HbA1c). Trial registration: The study was registered on clinicaltrials.gov with ID: NCT04285450.

1 February 2019 in Antiviral Therapy
Verified
Journal Article
Closed access
MAMogeb M Al-Nahari
Mogeb M Al-Nahari
MAMaggie M Abbassi
Maggie M Abbassi
FEFatma Se Ebeid
Fatma Se Ebeid
MHMohamed Hassany
Mohamed Hassany
MEManal H El-Sayed
Manal H El-Sayed
SFSamar F Farid
Samar F Farid
Background: Daclatasvir has potent antiviral activity against HCV infection when used in combination with sofosbuvir, however, its pharmacokinetics have not been described in adolescents. The aim is to determine the pharmacokinetic parameters of daclatasvir in adolescents, and to develop a population pharmacokinetic (PopPK) model. Methods: Seventeen adolescent patients with genotype-4 chronic HCV infection received once daily oral daclatasvir 60 mg in combination with 400 mg sofosbuvir for 12 weeks. Steady state concentrations were determined. Non-compartmental and population PK were determined. Results: The average PK parameters calculated by non-compartmental analysis (NCA): maximum plasma concentration (C max ), area under the curve (AUC), apparent oral volume of distribution (V/F), apparent oral clearance (CL/F) and half-life (T 1/2 ) were 1,092 ng/ml, 11,178 ng/ml•h, 55 l, 4.5 l/h and 8.5 h, respectively. Daclatasvir was best described by one compartment structural PK model with zero order absorption and first-order elimination. The absorption rate constant (K 0 ), V/F, and CL/F of the final PopPK model of daclatasvir were 1.5/h, 52 l and 4.7 l/h, respectively. Body weight and serum albumin had significant effect on the V/F parameter. Conclusions: Body weight and serum albumin were the major determinants of daclatasvir V/F in this population. PK parameters were comparable to those reported in adult HCV patients, demonstrating that 60 mg daclatasvir is an appropriate dose for adolescents. ClinicalTrials.gov NCT03540212.

15 February 2024 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
MEMarwa G. Elhennawy
Marwa G. Elhennawy
YAYosri Akl
Yosri Akl
MAMaggie Abbassi
Maggie Abbassi
NSNirmeen A. Sabry
Nirmeen A. Sabry
Purpose: Interstitial lung diseases (ILDs) are caused by inflammation and/or fibrosis of alveolar walls resulting in impaired gas exchange. Hypersensitivity pneumonitis (HP) is the third most common type of ILDs. Corticosteroids are the mainstay treatment for HP. The use of intramuscular (IM) betamethasone or intravenous (IV) dexamethasone as weekly pulse doses has shown higher benefit than daily oral prednisolone for HP patients. The aim of this study is to directly compare different corticosteroids in terms of effectiveness and in monetary values and perform an economic evaluation. Methods: One hundred and seven patients were tested for pulmonary function tests (PFTs) and inflammatory markers to assess the treatment effectiveness. A cost-effectiveness analysis (CEA) was performed. ICERs between 3 treatment groups were calculated. Results: Post treatment, Krebs von den Lungen-6 (KL-6) levels significantly improved in betamethasone group from 723.22 ± 218.18 U/ml to 554.48 ± 129.69 U/ml (p = 0.001). A significant improvement in erythrocyte sedimentation rate (ESR) occurred in the dexamethasone group from 56.12 ± 27.97 mm to 30.06 ± 16.04 mm (p = 0.048). A significant improvement in forced expiratory volume (FEV1), forced vital capacity (FVC) and six-minute walk distance (6MWD) was observed within the three treatment groups. A significant improvement in oxygen desaturation percentage (SpO2) occurred within dexamethasone and betamethasone groups. Betamethasone and dexamethasone were found more cost-effective than prednisolone as their ICERs fell in quadrant C. Furthermore, ICER between betamethasone and dexamethasone was performed; a small difference in cost was found compared to the higher benefit of betamethasone. Conclusion: Betamethasone and dexamethasone were found to be more effective than prednisolone in improving the inflammatory reaction and the clinical features of HP patients. Betamethasone was found to be the best intervention in terms of cost against the effect.

1 December 2018 in Bulletin of Faculty of Pharmacy, Cairo University
Verified
Journal Article
Open access
NENoha Elkassas
Noha Elkassas
MAMaggie Abbassi
Maggie Abbassi
SFSamar Farid
Samar Farid
Physicians’ perception of the role of the clinical pharmacist role plays a cornerstone in accepting interventions suggested by pharmacists to correct DRPs and in complying with guidelines of a pharmacist-led Antibiotic stewardship program (ASP). This study aimed at evaluating the acceptance of physicians’ to pharmacists interventions to antibiotic prescribing and the change in antibiotic consumption in Al-Haram general hospital Intensive care unit (ICU). This study was performed in Al-Haram general hospital ICU from July 2014 till December 2015. Medication review of antibiotics started in Al-Haram hospital ICU in July 2014 by responsible clinical pharmacists. An on-job physician education program about antibiotics started in June 2015. Implementation of ASP started in July 2015. The antibiotic related interventions and response of physicians to interventions were recorded all along the study period. The pattern of physicians’ acceptance along with antibiotic consumption (in Daily define dose per 1000 patient-days) were reported. The number of accepted interventions had increased along the study. The overall antibiotic consumption increased after implementation of ASP, however the individual pattern of antibiotic prescribing changed. The physicians in Al-Haram hospital appeared to accept the role of clinical pharmacist in correcting antibiotic-related DRPs as well as in implementing ASP.